

Claudia Sievers

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7001354/publications.pdf>

Version: 2024-02-01

10
papers

416
citations

1040056

9
h-index

1372567

10
g-index

10
all docs

10
docs citations

10
times ranked

835
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. PLoS Medicine, 2020, 17, e1003348.	8.4	31
2	PARP-1 deregulation in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731989460.	1.0	10
3	Prediction of natalizumab anti-drug antibodies persistency. Multiple Sclerosis Journal, 2019, 25, 392-398.	3.0	10
4	Dimethyl fumarate influences innate and adaptive immunity in multiple sclerosis. Journal of Autoimmunity, 2018, 86, 39-50.	6.5	63
5	Monocyte NOTCH2 expression predicts IFN- γ immunogenicity in multiple sclerosis patients. JCI Insight, 2018, 3, .	5.0	46
6	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. PLoS ONE, 2017, 12, e0170395.	2.5	34
7	Natalizumab-induced POU2AF1/Spi-B upregulation. Neurology: Neuroimmunology and NeuroInflammation, 2016, 3, e223.	6.0	27
8	MiR-126: a novel route for natalizumab action?. Multiple Sclerosis Journal, 2014, 20, 1363-1370.	3.0	36
9	Unraveling Natalizumab Effects on Deregulated miR-17 Expression in CD4 ⁺ T Cells of Patients with Relapsing-Remitting Multiple Sclerosis. Journal of Immunology Research, 2014, 2014, 1-11.	2.2	48
10	Altered microRNA expression in B lymphocytes in multiple sclerosis. Clinical Immunology, 2012, 144, 70-79.	3.2	111